Skip to main content

Table 2 The most advanced biological preparations used in asthma

From: Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly

Drug Target Function
Atrakincept Anti-IL4 Binds IL-4 thus blocking the interaction with its receptor. Reduces the proliferation of Th2 lymphocytes. Phase II
Pascolizumab
Benralizumab Anti IL-5 receptor Reduces the proliferation and activation of eosinophils. Phase II
Daclizumab Anti CD-25 Blocks the receptor for IL-2
Kerliximab Anti CD-4 Reduces the proliferation of CD4+ lymphocytes. Phase II
Mepolizumab Anti IL-5 Reduces the proliferation and activation of eosinophils. Phase III
Reslizumab
Omalizumab Anti IgE Complexes circulating IgE and impedes their binding to receptor. Commercialized
Pitakinra IL-4 mutein Competes with IL-4 and IL-13 receptor. Phase III